Guidance Is Sparse for Nonmotor PD Symptoms

BY KATE JOHNSON

Nonmotor symptoms of Parkinson’s disease remain underdiagnosed despite their widespread occurrence, which is the impetus behind new treatment guidelines from the American Academy of Neurology. “Nonmotor symptoms are an integral part of this syndrome. These symptoms can be as troublesome as motor symptoms and impact activities of daily living, though they are often underrecognized by health care professionals,” wrote Dr. Theresa A. Zesiewicz, lead author of the guidelines and professor of neurology at the University of South Florida, Tampa (Neurology 2010;74:924-31).

Treatment of depression, dementia, and psychosis in Parkinson’s disease (PD) has been addressed in a previous guideline (Neurology 2006;66:996-1002), as has treatment of PD-related salivary with botulinum toxin (Neurology 2008;70:1707-14).

However, there are many other nonmotor symptoms for which there is a paucity of research concerning treatment, wrote Dr. Zesiewicz and her colleagues. “The disease process of PD certainly contributes to many nonmotor symptoms, including autonomic dysfunction (orthostatic hypotension, gastrointestinal symptoms), depression, sexual dysfunction, and sleep dysfunction,” said Dr. Zesiewicz in an interview. “However, medications used to treat PD can contribute to other nonmotor symptoms. For example, the use of some PD medications can contribute to excessive daytime sleepiness, while others can cause insomnia.”

In general, the treatment of most nonmotor PD symptoms should mirror treatments given to non-PD patients, because “research is not currently available to support or refute their use specifically in PD patients,” she said. The new guidelines provide evidence-based recommendations for the treatment of only four conditions: erectile dysfunction, constipation, restless legs syndrome, and fatigue.

A wide range of nonmotor symptoms were reviewed for the guidelines, including autonomic dysfunction such as gastrointestinal disorders, orthostatic hypotension, sexual dysfunction, and urinary incontinence; sleep disorders such as restless legs syndrome, periodic limb movements of sleep, excessive daytime somnolence, insomnia, REM sleep behavior disorder; fatigue; and anxiety.

After a literature search to capture articles on these symptoms published in 1966-2008, a panel review deemed 46 papers relevant for the development of evidence-based recommendations, concluding that there was insufficient evidence to make recommendations on the treatment of urinary incontinence, orthostatic hypotension, insomnia, REM sleep behavior disorder, and anxiety.

For the treatment of erectile dysfunction in PD, the authors recommend that sildenafil citrate (50 mg) “is possibly efficacious.” Sexual dysfunction is common in both men and women with PD, they wrote. “Dysautonomia manifests as erectile dysfunction (ED) but also as reduced genital sensitivity and lubrication and difficulties reaching orgasm.” Only one controlled clinical trial for the treatment of ED was available for review, however.

For constipation, they concluded that isosmotic macrogol (polyethylene glycol) “possibly improves constipation in PD.” Four studies evaluating the efficacy of pharmacologic agents for PD-related constipation were reviewed, and the recommendation is based on one class II study.

Regarding PD-related sleep dysfunction, the authors found sufficient evidence to make treatment recommendations for excessive daytime somnolence (EDS), and restless leg syndrome or periodic limb movements of sleep.

Based on the results of two class I studies, they recommend modafinil to improve patients’ perceptions of wakefulness, although “it is ineffective in objectively improving EDS as measured by objective tests,” they added. In addition, they said, levodopa/carbidopa “probably decreases the frequency of spontaneous nighttime leg move-
Many clinical and functional imaging studies of patients with PD that have dopamine dysregulation syndrome and PD, patients with PD do have a risk for impulse control disorders that share features with addiction,” they cautioned.

“The same rules for treating PD patients with these medications would apply as when treating any patients, in particular careful monitoring of drug interactions and taking comorbidity conditions into consideration,” Dr. Zesiewicz noted.

“Of course, it is important to recognize that the treatments recommended are not the only available treatments,” commented Dr. Ronald B. Postuma, a PD researcher and assistant professor of neurology at the Montreal General Hospital. “The guidelines focus only on therapies that have good randomized controlled trial evidence. All experienced clinicians will recognize several useful treatments that are not in the recommendations because of incomplete evidence,” he said in an interview.

Disclosures: Dr. Zesiewicz reported receiving funding for travel and for serving on speakers bureau from Boehringer Ingelheim and Teva Pharmaceutical Industries Ltd. She also reported receiving research support from various pharmaceutical companies.

It’s never too early to have the “insulin talk”

Some conversations may be hard to initiate. Take the “insulin talk,” for example. According to the American Diabetes Association, insulin is the most effective agent for lowering blood glucose. It works as part of an overall diabetes treatment plan, which may include diet, exercise, and other diabetes medication.

Having the “insulin talk” early may help patients accept insulin as a potential treatment option to help them achieve their A1C goals.

The results of having a positive “insulin talk” can be impactful: in a survey, about 80% of patients with type 2 diabetes on OADs said they’d consider taking insulin if their doctor recommended it. So by starting the dialogue now, you can help your patients have a better understanding of insulin as an effective treatment option for lowering blood glucose.

Insulin—a chance for successful glycemic control, not a punishment for failure

Patients may focus on blaming themselves for their uncontrolled blood glucose, but you can help them focus on turning this negative mindset into positive action for managing their disease. The United Kingdom Prospective Diabetes Study showed that by the time patients with type 2 diabetes are diagnosed, they may already have lost up to 50% of their beta-cell function, and this function may continue to decline.

Because the disease is progressive, many patients with type 2 diabetes may eventually need insulin to achieve or maintain glycemic control. But by the time patients with type 2 diabetes are prescribed insulin, they may have had diabetes for 10 to 15 years and may already have complications due to a prolonged period of uncontrolled blood glucose. Starting insulin earlier in the disease continuum for appropriate patients can help improve glycemic control.

Controlling blood glucose can reduce the risk of diabetes-related complications.

Treatment plans and glycemic targets should be individualized for each patient.

Insulin is indicated to help improve glycemic control in patients with diabetes mellitus.

Important Safety Information About Insulin

Possible side effects may include blood glucose levels that are too low, injection site reactions, and allergic reactions, including itching and rash. Other medications and supplements could change the way insulin works. Glucose monitoring is recommended for patients with diabetes.

THE “INSULIN TALK”

Have the talk early and as needed, to help destigmatize insulin:

• Reassure patients that using insulin doesn’t mean failure and that insulin may help replace what the body is no longer adequately making

• Turn the negative mindset of failure into a positive opportunity to take personal control of A1C

Put insulin therapy in context:

• Explain the benefits of maintaining blood glucose goals and the risks associated with insulin therapy

• Talk about how insulin may be worth the effort—insulin is an effective treatment option that works as part of an overall treatment plan to lower blood glucose

Identify patients’ personal obstacles and help defuse the “scary” factor:

• Today’s insulin injections generally cause little discomfort and are administered using small, thin needles

• Insulin pens make insulin more convenient to administer and are discreet

• Insulin dose may need to be adjusted up or down over the course of treatment depending on how a patient’s body responds

INSULIN
IMPROVING BLOOD GLUCOSE CONTROL SHOULDN’T WAIT

Learn more at www.RethinkInsulin.com

© 2010 sanofi-aventis U.S. LLC

References:

Insulin is an effective treatment option that works as part of an overall treatment plan to lower blood glucose.

Insulin—a chance for successful glycemic control, not a punishment for failure.

It’s never too early to have the “insulin talk”.

Some conversations may be hard to initiate. Take the “insulin talk,” for example. According to the American Diabetes Association, insulin is the most effective agent for lowering blood glucose.

It’s never too early to have the “insulin talk.” Some conversations may be hard to initiate. Take the “insulin talk,” for example. According to the American Diabetes Association, insulin is the most effective agent for lowering blood glucose. It works as part of an overall diabetes treatment plan, which may include diet, exercise, and other diabetes medication.

Having the “insulin talk” early may help patients accept insulin as a potential treatment option to help them achieve their A1C goals.

The results of having a positive “insulin talk” can be impactful: in a survey, about 80% of patients with type 2 diabetes on OADs said they’d consider taking insulin if their doctor recommended it. So by starting the dialogue now, you can help your patients have a better understanding of insulin as an effective treatment option for lowering blood glucose.

Insulin—a chance for successful glycemic control, not a punishment for failure.

Patients may focus on blaming themselves for their uncontrolled blood glucose, but you can help them focus on turning this negative mindset into positive action for managing their disease. The United Kingdom Prospective Diabetes Study showed that by the time patients with type 2 diabetes are diagnosed, they may already have lost up to 50% of their beta-cell function, and this function may continue to decline.

Because the disease is progressive, many patients with type 2 diabetes may eventually need insulin to achieve or maintain glycemic control. But by the time patients with type 2 diabetes are prescribed insulin, they may have had diabetes for 10 to 15 years and may already have complications due to a prolonged period of uncontrolled blood glucose. Starting insulin earlier in the disease continuum for appropriate patients can help improve glycemic control. Controlling blood glucose can reduce the risk of diabetes-related complications.

Treatment plans and glycemic targets should be individualized for each patient.

Insulin is indicated to help improve glycemic control in patients with diabetes mellitus.

Important Safety Information About Insulin.

Possible side effects may include blood glucose levels that are too low, injection site reactions, and allergic reactions, including itching and rash. Other medications and supplements could change the way insulin works. Glucose monitoring is recommended for patients with diabetes.

THE “INSULIN TALK”

Have the talk early and as needed, to help destigmatize insulin:

• Reassure patients that using insulin doesn’t mean failure and that insulin may help replace what the body is no longer adequately making

• Turn the negative mindset of failure into a positive opportunity to take personal control of A1C

Put insulin therapy in context:

• Explain the benefits of maintaining blood glucose goals and the risks associated with insulin therapy

• Talk about how insulin may be worth the effort—insulin is an effective treatment option that works as part of an overall treatment plan to lower blood glucose

Identify patients’ personal obstacles and help defuse the “scary” factor:

• Today’s insulin injections generally cause little discomfort and are administered using small, thin needles

• Insulin pens make insulin more convenient to administer and are discreet

• Insulin dose may need to be adjusted up or down over the course of treatment depending on how a patient’s body responds.

INSULIN
IMPROVING BLOOD GLUCOSE CONTROL SHOULDN’T WAIT

Learn more at www.RethinkInsulin.com

© 2010 sanofi-aventis U.S. LLC

References:

Insulin is an effective treatment option that works as part of an overall treatment plan to lower blood glucose.

Insulin—a chance for successful glycemic control, not a punishment for failure.

It’s never too early to have the “insulin talk.” Some conversations may be hard to initiate. Take the “insulin talk,” for example. According to the American Diabetes Association, insulin is the most effective agent for lowering blood glucose. It works as part of an overall diabetes treatment plan, which may include diet, exercise, and other diabetes medication.

Having the “insulin talk” early may help patients accept insulin as a potential treatment option to help them achieve their A1C goals.

The results of having a positive “insulin talk” can be impactful: in a survey, about 80% of patients with type 2 diabetes on OADs said they’d consider taking insulin if their doctor recommended it. So by starting the dialogue now, you can help your patients have a better understanding of insulin as an effective treatment option for lowering blood glucose.

Insulin—a chance for successful glycemic control, not a punishment for failure.

Patients may focus on blaming themselves for their uncontrolled blood glucose, but you can help them focus on turning this negative mindset into positive action for managing their disease. The United Kingdom Prospective Diabetes Study showed that by the time patients with type 2 diabetes are diagnosed, they may already have lost up to 50% of their beta-cell function, and this function may continue to decline.

Because the disease is progressive, many patients with type 2 diabetes may eventually need insulin to achieve or maintain glycemic control. But by the time patients with type 2 diabetes are prescribed insulin, they may have had diabetes for 10 to 15 years and may already have complications due to a prolonged period of uncontrolled blood glucose. Starting insulin earlier in the disease continuum for appropriate patients can help improve glycemic control. Controlling blood glucose can reduce the risk of diabetes-related complications.

Treatment plans and glycemic targets should be individualized for each patient.

Insulin is indicated to help improve glycemic control in patients with diabetes mellitus.

Important Safety Information About Insulin.

Possible side effects may include blood glucose levels that are too low, injection site reactions, and allergic reactions, including itching and rash. Other medications and supplements could change the way insulin works. Glucose monitoring is recommended for patients with diabetes.

THE “INSULIN TALK”

Have the talk early and as needed, to help destigmatize insulin:

• Reassure patients that using insulin doesn’t mean failure and that insulin may help replace what the body is no longer adequately making

• Turn the negative mindset of failure into a positive opportunity to take personal control of A1C

Put insulin therapy in context:

• Explain the benefits of maintaining blood glucose goals and the risks associated with insulin therapy

• Talk about how insulin may be worth the effort—insulin is an effective treatment option that works as part of an overall treatment plan to lower blood glucose

Identify patients’ personal obstacles and help defuse the “scary” factor:

• Today’s insulin injections generally cause little discomfort and are administered using small, thin needles

• Insulin pens make insulin more convenient to administer and are discreet

• Insulin dose may need to be adjusted up or down over the course of treatment depending on how a patient’s body responds.